Disease Landscape and Forecast 인사이트

Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in non-inhibitor patients) and bypass agents (in…

A wide array of drugs is available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Giant cell arteritis (GCA) is an autoimmune disease marked by inflammation of blood vessels in the head and neck, especially the temporal arteries, leading to persistent headaches, flu-like…

The approvals of anti-PD-1/PD-L1 therapies—Keytruda (Merck & Co.), Opdivo (Bristol Myers Squibb), and Bavencio (Merck KGaA)—and antibody-drug conjugates—Padcev (Seagen / Astellas) and…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem-cell disorders that disrupt normal hematopoiesis in the bone marrow. All pharmacological approaches to treating…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and, ultimately, destruction of the interlobular bile ducts; this process is…

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal manifestations…

Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus, characterized by an accumulation of eosinophils. It can cause difficulty with swallowing food and has…

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more-potent biologics and/or…

Adult psoriasis treatment represents an increasingly lucrative market for biologics in the moderate to severe population, in which conventional systemic and topical treatments alone are not…

TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics (i.e., Takeda’…